#NASH

For people with NAFLD or NASH, treating metabolic problems may offer benefits beyond liver disease.

In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.

Colorectal cancer often spreads to the liver, especially when patients have fatty liver disease. New research may help explain this link.

People who used cholesterol-lowering medications had a 40% lower risk for liver disease progression.

VK2809 and pegozafermin are among several medications coming through the pipeline for fatty liver disease

A second meta-analysis found that people with cirrhosis had higher COVID mortality.

Individuals with fatty liver disease were more likely to need daytime naps and sleeping pills.

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

Some 20% of those with NAFLD also showed signs of liver fibrosis.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.

Another study found that children with fatty liver disease are at high risk for diabetes.

People with a tendency to be active later in the day may be at greater risk for severe NAFLD.

Non-alcoholic fatty liver disease is substantially more common among men compared with women.

Second- and third-generation individuals in Los Angeles had a 35% and 61% higher risk, respectively, than those born in Mexico.